Neurocrine Biosciences (NASDAQ:NBIX) is up 8% premarket following its Q2 report released after the close yesterday. Highlights:
Revenues were up 89% to $183.6M. Ingrezza sales were up 86% to $180.5M.
Net income: $51.3M (+871%); EPS: $0.54 (+871%).
Previously: Neurocrine Biosciences EPS beats by $0.32, beats on revenue(July 29)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.